000 01723 a2200445 4500
005 20250517201810.0
264 0 _c20180723
008 201807s 0 0 eng d
022 _a1178-1998
024 7 _a10.2147/CIA.S152701
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aYang, Pei-Shan
245 0 0 _aAn open-label, prospective interventional study of the tolerability and efficacy of 0.4 mg oral tamsulosin oral controlled absorption system in men with lower urinary tract symptoms associated with benign prostatic hyperplasia who are unsatisfied with treatment with 0.2 mg tamsulosin.
_h[electronic resource]
260 _bClinical interventions in aging
_c2018
300 _a235-242 p.
_bdigital
500 _aPublication Type: Clinical Trial, Phase IV; Journal Article; Randomized Controlled Trial
650 0 4 _aAdministration, Oral
650 0 4 _aAged
650 0 4 _aAged, 80 and over
650 0 4 _aDrug Tolerance
650 0 4 _aHumans
650 0 4 _aLower Urinary Tract Symptoms
_xdrug therapy
650 0 4 _aMale
650 0 4 _aMiddle Aged
650 0 4 _aPatient Satisfaction
650 0 4 _aProspective Studies
650 0 4 _aProstatic Hyperplasia
_xcomplications
650 0 4 _aQuality of Life
650 0 4 _aSulfonamides
_xadministration & dosage
650 0 4 _aTamsulosin
650 0 4 _aTreatment Outcome
650 0 4 _aUrination
_xdrug effects
650 0 4 _aUrological Agents
_xadministration & dosage
700 1 _aChen, Chien-Lun
700 1 _aHou, Chen-Pang
700 1 _aLin, Yu-Hsiang
700 1 _aTsui, Ke-Hung
773 0 _tClinical interventions in aging
_gvol. 13
_gp. 235-242
856 4 0 _uhttps://doi.org/10.2147/CIA.S152701
_zAvailable from publisher's website
999 _c28087593
_d28087593